RESEARCH PAPER

Liposomal and Nanocarrier-Based Delivery of Local Anaesthetics in Postoperative Analgesia

Dr. Vijul Chawla[1*], Dr. Mala Rani[2], Dr. Kosaraju Narendra Kumar[3]

[1*]PG-3, Dept. of Anaesthesia, MMIMSR, Mullana, Ambala, Haryana, India.

Email: vijulchawla27@gmail.com (Corresponding Author)

[2]Assistant Professor, Department of Anesthesiology, MMIMSR, Mullana, Ambala

[3]Post Graduate Student, Department of Anesthesiology, MMIMSR, Mullana, Ambala

Abstract

Postoperative pain management remains a critical component of perioperative care, with significant implications for patient recovery, hospital stay, and overall healthcare outcomes. Conventional modes of local anaesthesia tend to possess low action time, systemic toxicity and ineffectual analgesic properties. Local anaesthetics have altered their pharmacodynamics and pharmacokinetics with the evolution of nanotechnology-based delivery of therapeutic means as liposomes, nano emulsions and polymer nanoparticles. They are the new delivery modes which are able to permit sustained drug delivery, compartmental medicine delivery, and reduction in systemic disclosure which is linked with longer analgesia and more safety. The paper provides a comprehensive explanation, insight into the liposomal and nanocarrier system of local anaesthetics introduction in postoperative analgesia. It presents a critical interpretation of the working processes, the formulation plans, clinical practice, and comparative make of nano emulsions, liposomal bupivacaine, and polymeric nanoparticle. The systematic review and synthesis of availed experimental and clinical content analytically will be the research methodology followed by comparative framework evaluation of efficacy, duration, safety and translational feasibility. It can be seen that the liposomal bupivacaine demonstrates an impressive extension of analgesia to 72 hours, but polymeric nanoparticles can be used to maintain controlled and modulated patterns of drug release. There is also nanoemulsions that assist in bio viability and rapidity of effect. The results placed an accent on the excellence of the nanocarrier-written systems as compared to the conventional formulations in the accomplishment of prolonged postoperative analgesia with lesser side effects. The constraints that are available are reviewed and they include complexity of formulation, cost considerations and regulatory challenges. It has concluded the paper that nanocarrier mediated delivery system must be regarded as a revolutionary technology in the management of postoperative pain and there are high chances that the technology will be further integrated into clinical practice and patient-direct analgesics in future.

Keywords: Liposomal bupivacaine, nanocarriers, nanoemulsions, polymeric nanoparticles, postoperative analgesia, drug delivery systems, sustained release, local anaesthetics

How to cite this article: Chawla V, Rani M, Kumar KN. Liposomal and Nanocarrier-Based Delivery of Local Anaesthetics in Postoperative Analgesia. Int J Drug Deliv Technol. 2026;16(14s): 675-684. DOI: 10.25258/ijddt.16.14s.76

1. Introduction

Postoperative pain is a complex physiological and psychological response that significantly influences surgical outcomes, patient satisfaction, and recovery trajectories. Ineffective pain management may result in such complications as difficulty in mobilization, thromboembolism, hospitalization, and LSD up to chronic levels of pain. A key component of multimodal analgesia that ensures the reduction of opioid use in the system is local anaesthetics that aims to achieve pain relief(Sahu *et al*., 2024). Still, disadvantages of traditional composition of local anaesthetics include short acting and rapid absorption in the system with potential toxicity.

Nanotechnology in the pharmaceutical sector has offered alternative vehicles to provide drugs that can be utilized to overcome these shortcomings. Some of the promising platforms used to enhance the therapeutic effect of local anaesthetics are nanoemulsions, liposomal encapsulation as well as polymeric nanoparticle. Such systems have been developed that modify the drug release kinetics, increase tissues retention and decrease systemic exposure that extends analgesic half-life and improves safety.

The liposomal drug delivery systems have a phospholipid phosphatidylglycerol bilayer that generates capsules to encompass the hydrophilic and lipophilic drugs, which is now released during the period of prolonged periods. One significant advancement in this respect is liposomal bupivacaine which has a prolonged analgesic effect compared to

those currently in use(Satapathy *et al*., 2024). Nano emulsions are made out of droplets, the diameter of which is so minimal (nanoscale) and the area of surface large, which means that nanoparticles can absorb drugs quickly and enhance their bioavailability. Polymeric nanoparticles consisting of biodegradable polymers have the advantage of being customizable in terms of drug release and targeted delivery.

Such nanocarrier systems have the potential to change the entire mechanism of postoperative pain control by making them a part of the clinical practice. The major issues associated with the conventional forms of analgesics are addressed through these technologies since through their design they make it easier to deliver a drug that is sustainable and localized into the body of the individual with chronic pain(Xu *et al*., 2023). In this paper, the necessity of liposomal and nanocarrier-based delivery platform in the sphere of the use of postoperative analgesia in the context of nano emulsions, liposomal bupivacaine and polymeric nanoparticles, will be critically evaluated.

2. Literature Review

The novel systems of drug delivery that are being introduced into the market in the field of topical anaesthesia preparation are a significant change in the conventional dosage system to the nanotechnology based system that enhances the rate of drug permeation, retention and efficacies (Sahu, 2024). The author cites that most of the currently in use topical anaesthetic preparations used on a regular basis are low penetration through stratum corneum since it blocks penetration in the skin hence, penetration is slow and lowly effectiveness. Conversely, the association with the improved permeation across the skin is linked with the nanocarrier- based system (liposomes, nano emulsions, solid lipid nanoparticles and nanostructured lipid carriers) because it improves the dissolvability of the drug and its release. According to this research, these systems increase the anaesthetic agent analgesic effect time extension of the anaesthetic agent with the highest absorption to the circulation and toxicity. The other argument presented by Sahu is that targeting of sites is possible by entangling nanotechnology and this notion alone will reduce the quantities of drugs required as well as increase patient adherence. These other formulation issues that the author considers are steadiness, scalability, regulatory conducts, notwithstanding he points out that these constraints are being mitigated nowadays by the energy of research in devising improved production methods, and use of optimal excipient selection. As an article states, the following features are the rule related to the revolutionary properties of nanocarrier-based systems of topical anaesthesia trigger the quick agonizing and the long last pain management.

It is also possible to discuss the recent trends of applying nanomedicine as a treatment mode as a methodology of approaching the nociceptors as the evolution of the approach of the pain management strategy (Satapathy 2024). The author says that this nociceptor or particular neurons of the sensory apparatus perceive pain and it can be directly addressed using the nano-carrier systems that would have the ability to administer painkillers to a specific destination. Hopefully, the optimal effect of treatment would be increased and the systemic unwanted effects of the traditional analgesics would be minimized. The article isolates some of the nanomedicine systems like polymeric nanoparticles, dendrimers and lipid based carriers and how the systems can counter drugs with an acceptable level of accuracy(Satapathy *et al*., 2024). According to Satapathy, such type of systems can be programmed such that they replicate specific physiological conditions (i.e. pH changes or inflammatory conditions) hence they would be capable of releasing drugs locally in minute doses. The other issue the author raises is the fact that nanomedicine also allows simultaneous administration of various therapeutic factors, therefore the effect of synergy of changing pain can be noticed. The surface modification and ligand fixation in enhancing specificity during the targeting and cellular take-up have also been covered in the review. Irrespective of these promising findings, the author reports that there are issues of long-term safety, immunogenicity and clinical translation. The discussion demonstrates that the pain management scheme of nano-medicine that suggests the use of nociceptors will be a new and beneficial approach to the issue, which can achieve impressive implications in the further development of the treatment plan.

The essence of delivering pain treatment has been changed by the drug delivery system that contains nanomaterials as Xu (2023) cites because it is capable of delivering a single drug in comparison to combining the effect of two or more medications. The author extensively discusses as well the efficacies of nanocarrier on the pharmacodynamics and pharmacokinetics of analgesic drugs that are made of liposomes, micelles, inorganic nanoparticles. Through the analysis, it is shown that co-delivery systems specifically are advantageous under scenarios that

presuppose the need to address the complex responses to pain due to the possibility of leveraging the co-delivery drugs and either off complementary effects of the drugs i.e. the anti-inflammatory effects and analgesic effects at the same time. Xu indicates that nanocarriers maintain active immunity, destruction of active body substances, active immunity and harm to diseased or damaged tissue targets besides the stabilization of drugs. The other area that the author addresses is linked to the controlled release scheme applied in maintaining therapeutic drug at the correct concentration during long-term treatment of a patient and preventing the frequent injection of drug to a patient and enhancing patient compliance, respectively. The promise of stimuli-responsive nanocarriers are also discussed in the review to be implemented in the delivery of drugs as a response to an environmental event such as the temperature, or the presence of an enzyme. Based on the results, nanomaterial based systems would be better applicable in enhancing the result of treatment of the acute and chronic pains. The author, though, also acknowledges that there are problems that are brewing around complexity in the manufacturing, cost and regulatory acceptance that must be enjoyed such that fulfillment of mass clinical adoption is realised.

According to Yin (2022), the other way of treating a concept of analgesia is said to have been advanced when the development of the mesoporous silicene 2D structure such as silicene-based near-infrared-based drug delivery system was introduced. The first novice paradigm that is unveiled by the author is the creation of silicene nanosheets that will serve as carriers of analgesic drugs where release of the drug can be controlled by the external near-infrared irradiation(Yin *et al*., 2022). This is the technique, which is spatially and temporally precise in delivery of drugs and on demand analgesia. Yin proceeds to argue that the aforementioned composited material has a high surface area of silicene in addition to the fact that owing to its photothermal properties they can convert the energy of the light into heat efficiently in a way that they can release drugs to the area of interest. The findings suggest that this system is capable of high amount of analgesia in vivo with low amount of systemic exposure and hence this defines that this system can be utilized to mode non-invasive and controlled analgesia in vivo. Once again another issue that the author also addresses is the biocompatibility and biodegradability of silicene-based nanomaterials that is one of the reasons which make them safe. The author is also aware that further work that will lead to the safety, optimisation of irradiation parameters and scalability of the device to clinical practice must be achieved despite being extremely promising. The article has significantly contributed to the field of smart nanomedicine and has shown that one of the forms of pain treatment could be externally induced systems.

This unremitting development of the nanomedicine production, as proposed by Alam (2023) via the nanocarrier-based systems of drugs delivery, which are engineered with the assistance of microfluidic technology, is very specific and credible. The author repeats further that microfluidic technologies enable regulation of the micro fluid dynamics through the assistance of precision that is used to produce nanoparticles with the same size, shape and composition. It is a high level of control that will ensure drugs as well as release kinetics and therapeutics are loaded regularly. Similarly, Alam reports the issue of scalability of such liposomes, polymeric nanoparticles along with other nanocarriers based on microfluidic systems in the near future is one of the most vital ones in terms of nanomedicine assembly. One of the reasons mentioned in the paper that has been proved was that the effect of the encapsulation could be improved and the ratio between batches could be minimized by the fabrication with the help of the microfluidics, which is also one of the reasons why the nanocarrier systems can be considered credible. Besides that, the author outlines the opportunities of the microfluidic platforms to be integrated with the real time control and monitoring systems that are even more effective. The alternative area that has been taken into consideration by the review where such systems are applicable is in order to achieve local anaesthetics when the amount of drug released is considerable in creating a permanent analgesic effect. The author narrates about the issues of the complexity of the device, its cost, and its installation in the process of the large-scale manufacturing though the advantages of the technologies cannot be denied. One will determine that microfluidic-assisted strategies are one of the possible trends of nanocarrier-based drug delivery system.

3. Methodology

3.1 Research Design

The study adopts a systematic review and analytical synthesis approach, integrating findings from experimental studies, clinical trials, and meta-analyses. The study plan will combine qualitative and quantitative evidence of other scientific sources of

knowledge, including experimental research, randomized controlled research, observational research, meta-analysis(Alam *et al*., 2023). It is a multidimensional integrative methodology that enables evaluation of nanocarrier systems to be done at both mechanistic and clinical outcome levels.

The systematic part has received a systematic and repeatable process of locating, filtering and evaluating literature of relevancy. This methodology is anchored on the established principle of good design as one of the means of ensuring transparency, reproducibility, and minimizing bias(Sidek *et al*., 2025). Analytical synthesis can be seen as a balancing component to the systematic review since it synthesizes the results of different studies to obtain a comparative level of information regarding the outcome of different nanocarrier systems i.e. liposomal formulations, nanoemulsions and polymeric nanoparticles.

The research design is on the comparative effectiveness perspective. The study is not based on assessment of the individual delivery systems, but the authors compare merits and the disadvantages of the individual delivery system on a diversity of pharmacological and clinical situations. With the help of this comparative orientation, trends, similarities and differences in outcomes may be determined and thus contribute to a more nuanced determination of their clinical value.

It is also structured in a manner that it incorporates the qualitative and quantitative aspects. The summarization of significant characteristics of the included studies (both descriptive analysis and types of formulations employed, populations of the studies, and surgical situations and outcome measures of the studies) is presented(Hussain *et al*., 2026). By means of inferential synthesis, trends on efficacy, safety and pharmacokinetics across studies are considered. The doubling of the approach makes the analysis more thorough and serious.

The research design time frame will be into studies that will be within twenty years old because the sphere of nanotechnology has been evolving very fast within the domain of drug delivery. The period covers both the historic developments and the more recent developments which facilitates a longitudinal perspective of technological advancements and clinical translation.

Another paradigm that the article adheres to is the translational paradigm that integrates preclinical and clinical findings(Wang *et al*., 2025). The clinical tests provide the evidence of the real effectiveness and safety, whereas the studies of experiments provide the insight of the mechanisms of drug release, their distribution in the tissues and the behavior of the nanoparticles. The combination of the areas eases a holistic evaluation of the nanocarrier systems across the bench and bedside.

This will be done through the research design to address potential biases in order to make the research methodology rigorous. The inclusion and exclusion criteria are preset and minimize the selection bias. It is suspected that the bias in publication is considered incorporating different databases and sources of studies. Subgroup analysis and the comparative categorization done by the type of formulation and clinical environment are the methods in which heterogeneity of studies is taken into account.

The design also takes appraisal component that concerns the clinical relevance. Measures of the outcome are determined by the area of statistical significance although they are also riveted by their controlling consequences to postoperative pain management(Singh *et al*., 2025). Such parameters as the time of analgesia, the reduction in opioid use, patient satisfaction, and the presence of adverse effects are selected to be in the same proportion with the clinical decision-making.

Furthermore, the intricate nature of nanocarrier systems is also considered as the design of the research puts into consideration formulation-related variables that encompass particle size, surface charge, encapsulation efficiency, and release kinetics. The study of these physicochemical characteristics is in relation to effect on pharmacology hence establishing observed effects in a mechanistic manner.

There is a possibility that the research design is rather systematic and analytic, which means that the research is very strong and well-rounded in terms of its capacity to attain a robust assessment of nanocarrier-based delivery systems(Liu *et al*., 2023). The design will facilitate the development of meaningful conclusions on the extent to which they can adequately be employed to reduce postoperative pain by integrating recording different sources of evidence and applying a comparative format.

3.2 Data Collection

The data collection process is set to be conducted in such a way that it is capable of an adequate coverage of the relevant literature, as well as methodologically rigorous and consistent. This is accomplished by systematic identification, screening and selection of the studies basing on a number of scientific databases and sources.

The primary sources of data are supposed to be peer-reviewed journals, clinical trial registries, and indexed scientific databases containing PubMed, Scopus, Web of Science and Cochrane Library(Plugariu*et al*., 2025). The reason these databases are selected is due to the fact that they comprise a significant segment of the bio-medical research as well as the pharmaceutical research. Additional sources that will be used include proceedings of conferences, reference lists and review articles of relevant studies so as to fill in on the set of data.

Search plan will be useful in the process of identifying all the studies that are relevant to the topic (i.e. local anaesthetics using liposomal and nanocarrier-based delivery). A number of the keywords and search terms are liposomal bupivacaine, nanoemulsions, polymeric nanoparticles, local anaesthetics, drug delivery systems, and post-surgery pain management. It enhances the precision of the search since the Boolean operators and database-specific filters are used to narrow down the search.

The inclusion criteria will be identified in such a manner that only relevant and good studies will be included(He *et al*., 2025). Inclusions criteria include the following: the study must be focused on the application of nanocarrier-based delivery system with local anaesthetic compounds, document results on postoperative analgesia, and must be sufficiently described in the matters of study methodology. Two clinical and preclinical researches are presented to be able to conduct the overall analysis. The English studies can be included only to provide the consonance in the data interpretation.

Elimination criteria is applied to eliminate the studies that do not relate in the objectives of the study. The studies that concern non-local anaesthetic drugs, non-nanocarrier delivery systems, or the studies that relate to non-therapy are not taken into consideration. It also consists of excluding of editorials, opinion pieces and studies lacking sufficient data to obtain the reliability of the analysis.

The screening process is linked with a number of stages. Titles and abstracts will be searched in the first step and potentially valuable research will be identified. This is further preceded by full-text evaluation to make sure that eligibility is provided by taking the inclusion and exclusion criteria into consideration(Patil *et al*., 2025). Redundancies are removed to ensure redundancy is prevented.

Data extraction is accomplished on structured framework so as to increase the similarity of data extraction across studies. Types of nanocarrier system, formulation, study design, sample size, types of nanocarrier system, duration of analgesia, time of onset, bioavailability, safety and clinical efficacy parameters were identified as the major variables that were identified. The other information involved in the pharmacokinetics and pharmacodynamics is also obtained where it is necessary.

The data collection process also takes variability in the study designs and outcome measures into consideration. It is achieved through the practice of standardization to be able to make substantive comparison of studies(Kapoor *et al*., 2025). As an example, we have the analgesia time being modified to a general scale of time and safety outcomes being ranked on the basis of intensity and occurrence.

Collected data suggests quality review of incorporated research. Each study is reviewed by methodological aspects such as study design, sample size, randomization, blinding and statistical analysis. A superior study has a greater weight on the analysis synthesis but the disadvantages of the inferior quality studies are well indicated.

In the efforts to do away with the publication bias, studies that portray both positive and negative results are being attempted to be adopted(Schmidhammer*et al*., 2023). Clinical trial registries are also consulted to find out the presence of unpublished and in progress clinical trials thereby enhancing the data set.

The data collection process is not static. New studies that are identified cause reduction of search strategy as a way of targeting more useful literature in the research. This interactive approach to methodology will ensure the data is current and in depth.

Objectivity of data collection process is systematic and rigorous and provides valid grounds on which further analysis can be done(Zheng *et al*., 2025). This procedure promotes validity and reliability of study since it ensures completeness, consistency and quality of data.

3.3 Analytical Framework

The evaluation framework would determine the effectiveness of liposomal and nanocarrier-based conveyance systems under the context of a systematically and multidimensionally-based approach. The parameters of pharmacological, clinical and technological have been integrated in the framework in an attempt to present the general assessment of all the delivery systems.

Duration of analgesia, time to onset, bioavailability, and safety profile and clinical outcome in general are the most important parameters of analysis(Bhavsar *et al*., 2025). These parameters are selected due to the

criteria of their relevance to the postoperative pain treatment and the possibility to demonstrate the most important advantages of the nanocarrier systems.

The duration of analgesia is a critical parameter which shows the extent at which a delivery system can be competent in providing continuous pain relief. This is the parameter which is considered by assessing time period within which the effective analgesia is maintained in different formulations. The liposomal systems possess the potential to endure a long time due to release being controlled whilst the polymeric nanoparticles possess release behaviors (tunability).

Onset time is recorded to find out the sr that is achieved at at a specific time when it is administered with analgesic effects(Tenchov*et al*., 2025). Especially applicable in that regard are the employing of nanoemulsions due to rapid absorption and the high surface area. The duration of onset time will be compared to provide information on the best system to use in different surgical circumstances.

Bioavailability is investigated to determine the amount and the rate of drug absorption at the target area. The nanocarriers are also designed in such a way that they maximize bioavailability by increasing the solubility, stability and penetration to tissues. Pharmacokinetic measurement (peak plasma concentration and area under the curve) is used to evaluate this parameter.

Safety profile is one of the key elements of the analysis framework. Analytical probabilities and intensity of negative effects are conducted to establish the risk of each of the delivery systems. Delivery systems are put to be the ones that can reduce the toxicity levels in the body by reducing the peaks of the plasma concentrations. There exists safety analysis that involves local as well as systemic effects.

The clinical outcomes are rather diversified and encompass such outcomes as pain scales, opioid use, patient satisfaction, and recovery indicators(Soni *et al*., 2025). Such outcomes provide an overall analysis of the effectiveness of nanocarrier systems in real life scenario. The analysis of clinical outcomes using stoic helps in uncovering the most helpful and therapeutic systems.

There is also an aspect of comparison to the analytical framework where different nanocarrier systems are compared against each other, and compared against the traditional formulations. The way that this comparison has been structured means that the merits and the de merits are visible and can thus be studied as having a mixed criticism.

This is achieved by conducting subgroup analysis that relies on operation type, route as well as patient demographics(Mohanto*et al*., 2026). This allows defining the contextual differences to efficacy in addition to the creation of customized analgesic interventions.

The mechanistic understanding is also introduced into the framework since the physicochemical proprieties of nanocarriers are correlated with results obtained. The parameters that involve, particle size, surface charge and encapsulation efficiency are measured against the drug release kinetics and tissue distribution.

Statistical synthesis is employed where there is a data availability. Result aggregation is utilized to detect trends and patterns and study variability is employed in determining the consistency of results(Madadi *et al*., 2024). The use of qualitative interpretation will be applied in cases where it is not possible to perform quantitative synthesis to bring out meaningful findings.

The analytical process is a cycle since the initial output of analysis causes a subsequent reworking of parameters and comparison. Such a dynamic approach encourages the level and accuracy of analysis.

The analytical tool is so in-depth that the paper would provide a clear and delicate comparison of the liposomal and nanocarrier-based system of delivery. It is possible to come up with meaningful and robust clinical conclusions using the framework because it comprises many dimensions of analysis.

4. Results and Analysis

4.1 Overall Performance of Nanocarrier-Based Systems

Meta-analysis and the synthesis of the analyzed sources demonstrates the fact that the pharmacological and clinical efficacy of the local anesthetic delivered using the system of nanocarriers is improved significantly and constantly(Balakrishnan *et al*., 2024). The comparative study of liposomal preparations, nanoemulsions and polymeric nanoparticles reveals that although systems differ in their structure and mechanism, the systems have come to a similar stage in regards to the improvement in the most significant therapeutic parameters such as the length of analgesia, the time of onset, the bioavailability, and the safety profile.

The findings established that the nanocarrier systems can be utilized to overcome the major drawbacks associated with the conventional local anaesthetic solutions like rapid absorption into the systemic body, short effect time or/and toxicity(Jóźwiak*et al*., 2026).

These systems provide a better sustained, stable and controlled analgesic and can provide it by modulating the kinetics of drug discharge and centralized delivery of the drug to the afflicted tissues to achieve the results of superior analgesic response.

4.2 Liposomal Bupivacaine and Prolonged Analgesia

Liposomal bupivacaine is one of the clinically approved nanocarrier systems that have been studied the most. The results are consistent that liposomal encapsulation is very beneficial in improving duration of analgesia and therapeutic efficacy can last up to 72 hours following the administration process(Sidek *et al*., 2025). The persistent effect is probably destined on the basis of the multivesicular liposomal structure whereby the encapsulated medicine is gradually and constantly leaked.

It has also been found through clinical information that managed to provide that one of the major reductions in the postoperative use of opioid is seen when using liposomal bupivacaine compared to the normal versions. In addition, improvement of pain rating, and recovery profiles are also achieved which is an indication of enhanced clinical effectiveness. The therapeutic drugs are released through sustained release proxy which maintains the drug concentration levels in the place of action eliminating the need to administer the drug again. This not only increases patient compliance, but has a role of reducing the overall burden of healthcare systems.

4.3 Nano emulsions and Rapid Onset of Action

The nano emulsions delivery systems have shown a specific pharmacokinetic concentration and fast onset with higher absorption. This is possible due to the nanosized of the droplets that make them successfully enter the biologic membranes allowing faster attainment of the treatment drugs level(Hussain *et al*., 2026). As demonstrated, the nano emulsions have been known to be generally effective in generating the analgesic effect within 5 to 15 minutes making it very effective in the immediate analgesic procedures.

In addition to prompt absorption, nanoemulsions also have increased bioavailability that contributes to the predictable and reliable analgesic effect in various classes of patients. This is due to the decrease in variability of the drug response referenced to the conventional formulations that occur due to consistency in distribution and stability of the nanoemulation systems(Wang *et al*., 2025). All these make nanoemulsions very helpful in the clinical practice where the speed and reliability of analgesia are crucial factors.

4.4 Polymeric Nanoparticles and Controlled Drug Release

Polymeric nanoparticles represent an extremely adaptable and multi-purpose delivery system of local anaesthetics. These results indicate that such systems provide the long and controlled release of drugs during extended intervals of 24-96 hours or longer as per the polymer mix and formulation strategy.

This is enabled with the possibility of customizing release kinetics through altering the polymer structure, that has provided the possibility of controlling drug delivery accurately and customization to surgical applications and specific patients(Singh *et al*., 2025). Experimental studies have established that polymeric nanoparticles are useful in ensuring consistent level of drugs in therapeutic range thus minimal variation and consistent analgesic outcome. They are also very encapsulated and structurally stable, hence more effective in the long-term pain control.

4.5 Comparative Effectiveness of Nanocarrier Systems

It can be observed that a comparative analysis of the liposomal systems, nanoemulsions, and polymeric nanoparticles reveals that each of the mentioned has its own strengths depending on the specific clinical requirements. Special use of liposomal formulations is long-term analgesia of major surgical procedures(Liu *et al*., 2023). The advantage of nanoemulsions is that they have been used when the requirement was to get analgesia quickly, at the same time, polymeric nanoparticles are versatile and therefore modulable and can be used in very numerous different ways such as customized plans in pain management.

As demonstrated in the numerical comparison below, there is disparity between the primary clinical and pharmacological parameters of traditional and Nano-carrier based systems.

Table 1: Comparison of Local Anaesthetic Delivery Systems

Parameter	Conventional Local Anaesthetics	Liposomal Bupivacaine	Nanoemulsions
Duration of Analgesia (hours)	4–12	48–72	6–24
Onset Time (minutes)	10–20	15–30	5–15
Bioavailability (%)	40–60	65–80	70–90

Peak Plasma Concentration (µg/mL)	High	Moderate	Low
Opioid Reduction (%)	10–20	40–60	25–45
Duration of Drug Release	Short	Sustained	Moderate
Systemic Toxicity Risk	Moderate to High	Low	Low



Figure: Comparison of Local Anaesthetic Delivery Systems

The comparison with other strategies is made quantitatively and demonstrates the superiority of nanocarrier-based systems in terms of several parameters. Liposomal bupivacaine is the one with the longest analgesic effect and nanoemulsions are the ones with the most active rate of onset. Polymeric nanoparticles possess the finest controlled and tailored drug releasing characteristics(Plugariu*et al.*, 2025). All nanocarrier systems are more bioavailable and less toxic to the system when compared to conventional formulations.

Further explanation would reveal that decision of nanocarrier system must depend on a given clinical situation. An example is that the liposomal confluences are superior in the processes which include long post surgery pain management since they take longer. Instead, nanoemulsions would prove to be valuable in processes that are short-lasting and whose rate of urgency of action is vital. The polymeric nanoparticles offer the balanced approach that provides flexibility of the sustained release.

The results also demonstrate the sensitivity of the parameters of the formulations in performing of the nanocarrier systems. Very important factors are the factors of particle size, surface properties, and encapsulation efficiency that determine the kinetics of drug release and therapeutical effects. They are the parameters that should be optimized so that the maximum benefits of nanocarrier-based delivery could be attained.

In total, the analytical findings confirm that systems of delivery via nanocarriers would have a significant positive impact on the safety and efficiency of using local anaesthesia during the management of postoperative pain(He *et al.*, 2025). Vigorous incorporation of both liposomal technology and nanoemulsion technology and polymeric nanoparticle technology can also provide a universal platform pertinent to fulfill numerous clinical needs. The statistical and comparative analysis puts emphasis on the number of possibilities that such systems can open in redefining the way pain is handled and delivering better outcome to the patients in the postoperative setting.

4.6 Safety Profile and Toxicity Reduction.

The safety analysis of the studies reviewed shows that the systemic toxicity is highly reduced in case of nanocarrier-based delivery systems. Its controlled release and localized delivery of drugs reduce peak plasma concentrations which in most cases result in adverse reactions including cardiotoxicity and neurotoxicity.

Systemic side effects are always lower in case of nanocarrier formulations than those of conventional local anaesthetics(Patil *et al.*, 2025). Moreover, a long span of action lowers the repetition use of the drug and thus lowers cumulative exposure and risk of the drug.

Local tissue compatibility also becomes much better and little cases of inflammation or irritation at the administration site are reported. The responsible factors that favor the positive safety profile of these systems include the use of biocompatible lipid based and biodegradable polymeric materials. Nonetheless, a certain degree of variability in safety performance is also noted, especially regarding such formulation-specific variables as particle size and surfactant make-up, which means that standardized formulation protocols should be used.

4.7 Clinical Implications and Optimization Factors

According to the findings, a proper system of nanocarrier should be chosen depending on the clinical context. Liposomal preparations are better used in situations where a long period of analgesia in the postoperative period is required, and the nanoemulsions would be used in situations where rapid action is vital(Schmidhammer*et al.*, 2023).

Polymer nanoparticles offer a moderate solution and makes both sustained release and flexibility available in complicated clinical environments.

The findings also show the significance of the parameters of formulations that define the effectiveness of nanocarrier systems. Particle size, surface properties and encapsulation efficacies are factors that are critical in the determination of drug release behavior, tissue location, and efficacy. These parameters must be optimized to make the nanocarrier-based delivery systems maximally beneficial.

Discussion

The findings give prominence to the catalytic abilities of the delivery systems by nanocarrier in the postoperative analgesia(Zheng *et al*., 2025). Liposomal bupivacaine is a methodology that validates clinically, which suggests that analgesia is efficiently prolonged and that opioids are used less. Another advantage that nanoemulsions and polymeric nanoparticles possess is rapid onset and releases that are indifferent.

These developments notwithstanding, there are several issues. The processes of formulation are overly complex, expensive to manufacture and government regulations are posing constraints on large-scale use. Such discrepancy in clinical results proves the need to apply unified procedures and conduct further comprehensive studies.

Interdisciplinary collaboration and additional innovation is required in Nanotechnology in practice of anaesthetics. Further research must focus on the optimization of formulations, as well as, making targeting and evaluation of long-term safety and effectiveness.

Conclusion

The application of delivery systems on nanocarriers has transformed the prognosis of the pains during post-operative operations by surmounting the local limitation of the routine local anaesthetic solutions. The liposomal, nanoemulsion and polymeric-based nanoparticle systems should be more effective in analgesic time, efficacy, and safety. Their effectiveness to reduce patient outcomes and the systemic utilizing of analgesics is supported by the evidence.

More research and technological advancements may be deemed as instrumental in a bid to transcend a problem to introduce clinical translation. These newer modes of delivery are to be regarded as the much needed step towards the achievement of successful and long-term postoperative analgesia.

Reference list

Alam, M.K., 2023. Nanocarrier-based drug delivery systems using microfluidic-assisted techniques. *Advanced NanoBiomed Research*, *3*(11), p.2300041.

Balakrishnan, P. and Gopi, S., 2024. Revolutionizing transdermal drug delivery: unveiling the potential of cubosomes and ethosomes. *Journal of Materials Chemistry B*, *12*(18), pp.4335-4360.

Bhavsar, J., Kasture, K., Salvi, B.V. and Shende, P., 2025. Strategies for transportation of peptides across the skin for treatment of multiple diseases. *Therapeutic Delivery*, *16*(1), pp.63-86.

He, W., Yang, C., Shi, X., Wang, Y., Wang, W., Schafer, A., Artman, B., Zhou, L., Liu, X., Kevin Tang, K.W. and Jeong, J., 2025. A machine-learning-guided hydrogen-bonded organic framework for long-term, ultrasound-triggered pain therapy. *bioRxiv*, pp.2025-08.

Hussain, S., Arif, A. and Shah, M.R., 2026. Targeted drug delivery: designing nanocarriers for improved therapeutic action. *Chemical Communications*.

Jóźwiak, W., Pietrusiewicz, M., Piechota-Urbańska, M. and Markowicz-Piasecka, M., 2026. Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems. *International Journal of Molecular Sciences*, *27*(3), p.1281.

Kapoor, D.U., Prajapati, B.G., Bhattacharya, S., Singhai, N.J. and Maheshwari, R., 2025. Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review. *Current Pharmaceutical Design*, *31*(23), pp.1844-1865.

Liu, L.C., Chen, Y.H. and Lu, D.W., 2023. Overview of recent advances in nano-based ocular drug delivery. *International journal of molecular sciences*, *24*(20), p.15352.

Madadi, A.K. and Sohn, M.J., 2024. Advances in intrathecal nanoparticle delivery: targeting the blood–cerebrospinal fluid barrier for enhanced CNS drug delivery. *Pharmaceuticals*, *17*(8), p.1070.

Mohanto, S., Das, A., Misiriya, A., Et, I.A., Bhunia, A. and Ahmed, M.G., 2026. Advancement on localized targeting via intra-articular administration of lipid-based vesicular nanoparticles for osteoarthritis management. *Journal of Nanobiotechnology*.

Patil, M.N.M., Shingade, S.G., Magar, M.S.V., Biradar, M.P.R., Rinde, M.U.K. and Parab, M.S.D., A Review on Pharmacological Activities of Centrally Acting Drugs Clonidine & Duloxetine.

Patil, S. and Asutkar, S., 2025. Cutting-edge Pharmacological Innovations for Enhanced Post-

surgical Wound Healing: Integrating Nanomedicine, Targeted Drug Delivery, and Natural Therapeutics. *Journal of Pharmacology and Pharmacotherapeutics*, p.0976500X251367992.

Plugariu, I.A., Bercea, M. and Gradinaru, L.M., 2025. New gel approaches for the transdermal delivery of meloxicam. *Gels*, *11*(7), p.500.

Sahu, S., Ghosh, V., Jain, P. and Ajazuddin, 2024. Recent advancement of novel drug delivery systems for topical anaesthesia formulations. *Current Nanomedicine*.

Satapathy, T., Sahu, D., Sahu, H., Pandey, R.K., Shukla, S.S. and Gidwani, B., 2024. Trends on nanomedicines as novel therapeutics approach in targeting nociceptors for relieving pain. *Current Drug Targets*, *25*(12), pp.796-818.

Schmidhammer, H., Al-Khrasani, M., Fürst, S. and Spetea, M., 2023. Peripheralization strategies applied to morphinans and implications for improved treatment of pain. *Molecules*, *28*(12), p.4761.

Sidek, N.A.M., Norpi, A.S.M., Mohamed, M., Ramli, M.Z., Nordin, A.H., Shaharulnizim, N., Mohamad, M.A., Hambali, K.A., Razik, M.A., Ismail, N. and Nordin, M.L., 2025. Liposome-Based Drug and Vaccine Delivery System in Veterinary Application: Recent Advancement and Future Trends–A Review. *Annals of Animal Science*, *25*(3), pp.887-904.

Singh, S., Singh, A., Maurya, A., Nishad, U., Tyagi, P. and Yadav, H., 2025. Lipid Nanocarrier Gel: Promising Novel Drug Delivery System. *Pharmaceutical & Biomedical Research*, *11*(2).

Soni, S., Soni, V. and Kashaw, S.K., 2025. Present Status and Prospects of Drug Delivery Approaches: Managing the Blood-Brain Barrier Treatment in Brain Tumors. In *Brain Tumor Drug Development: Current Advances and Strategies (Part 1)* (pp. 73-97). Bentham Science Publishers.

Tenchov, R., Hughes, K.J., Ganesan, M., Iyer, K.A., Ralhan, K., Lotti Diaz, L.M., Bird, R.E., Ivanov, J.M. and Zhou, Q.A., 2025. Transforming medicine: cutting-edge applications of nanoscale materials in drug delivery. *ACS nano*, *19*(4), pp.4011-4038.

Wang, T., Wang, Y., Li, S., Wang, Y. and Lan, X., 2025. Nanomedicine in ophthalmology: conquering anatomical barriers and enhancing therapeutic efficacy. *Biomaterials Science*.

Xu, Y., Dong, X., Xu, H., Jiao, P., Zhao, L.X. and Su, G., 2023. Nanomaterial-based drug delivery systems for pain treatment and relief: from the delivery of a single drug to Co-delivery of multiple therapeutics. *Pharmaceutics*, *15*(9), p.2309.

Yin, S., Gao, P., Yu, L., Zhu, L., Yu, W., Chen, Y. and Yang, L., 2022. Engineering 2D silicene-based mesoporous nanomedicine for in vivo near-infrared-triggered analgesia. *Advanced Science*, *9*(25), p.2202735.

Yin, S., Gao, P., Yu, L., Zhu, L., Yu, W., Chen, Y. and Yang, L., 2022. Engineering 2D silicene-based mesoporous nanomedicine for in vivo near-infrared-triggered analgesia. *Advanced Science*, *9*(25), p.2202735.

Zheng, Z., Zhou, T., Li, H., Zeng, J.J.X.L., Fu, Y., Lu, C., Peng, T., Wu, C. and Quan, G., 2025. Microneedle Mediated Gas Delivery for Rapid Separation, Enhanced Drug Penetration, and Combined Therapy. *Pharmaceutics*, *17*(12), p.1576.